查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1935644

EGFR檢測市場按檢測類型、樣本類型、應用和最終用戶分類，全球預測，2026-2032年

EGFR Tests Market by Test Type, Sample Type, Application, End-Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 EGFR 檢測市場在 2025 年的價值為 17 億美元，在 2026 年成長至 18.4 億美元，複合年成長率為 8.48%，到 2032 年將達到 30.1 億美元。

關鍵市場統計數據
基準年 2025 17億美元
預計年份：2026年 18.4億美元
預測年份 2032 30.1億美元
複合年成長率 (%) 8.48%

關於 EGFR 診斷的權威指南，重點關注臨床影響、檢查室實施實際情況以及技術與患者照護路徑的融合。

表皮生長因子受體 (EGFR) 檢測已從一項小眾分子檢測發展成為精準癌症治療的核心支柱，指導標靶治療並影響多種腫瘤類型的臨床路徑。近年來，隨著臨床醫生尋求更快、更全面、更微創的方法來檢測可治療的 EGFR 突變，診斷流程也迅速發展。因此，檢查室運作、分子病理團隊和診斷試劑研發人員都在不斷調整，以平衡分析靈敏度和臨床效用，同時確保檢測結果能夠無縫整合到治療決策中。

技術成熟、臨床指南不斷演變以及支付方期望的變化正在共同重塑 EGFR 檢測方法和治療路徑。

EGFR檢測領域正經歷著變革性的轉變，這主要歸因於多種因素的共同作用：技術的成熟、臨床指南的更新以及以價值為導向的醫療模式的演進。次世代定序和高靈敏度PCR檢測正超越單標靶檢測的限制，實現無需預設假設的多重檢測，從而能夠捕捉更廣泛的可靶向突變。這項轉變提升了EGFR檢測在早期診斷和抗藥性監測的臨床價值，並正在重塑腫瘤學領域的檢測流程。

分析關稅變化對診斷供應鏈、採購決策以及EGFR檢測服務連續性的下游營運和策略影響

新關稅制度和貿易政策調整的實施將對診斷供應鏈的運作和成本結構產生重大影響，尤其是在試劑供應、設備採購和跨境服務模式方面。關稅會增加進口試劑和設備的到岸成本，迫使實驗室最佳化供應商組合、重新談判採購條款並考慮本地採購方案。這又會影響檢測項目的選擇以及各醫療機構採用新技術的速度。

基於詳細的細分資訊，分析檢測方法、檢體策略、臨床應用和最終用戶需求，制定有針對性的診斷策略。

清楚了解市場區隔趨勢對於使產品開發和商業策略與臨床及檢查室需求保持一致至關重要。從檢測類型來看，免疫組織化學、原位雜合反應、次世代定序定序和基於PCR的檢測在診斷流程中佔據不同的位置，這反映了它們在分析解析度、週轉時間和成本方面的權衡。免疫組織化學和原位雜合反應通常作為基於病理學的初步篩檢工具，而基於PCR的檢測和次世代定序則提供高解析度的分子表徵，以輔助選擇標靶治療。

各主要地區監管環境、報銷模式和基礎設施的差異會影響EGFR診斷的普及性和策略規劃。

區域趨勢將對EGFR診斷的監管路徑、報銷框架和實施時間表產生重大影響。在美洲，完善的臨床指南和廣泛的腫瘤學網路促進了先進分子檢測的早期臨床應用，而獲得認證的參考實驗室和綜合醫療系統則為分析性能和報告設定了高標準。這種環境有利於採用多重檢測方法和結構化的結果解讀，從而支持精準治療決策。

深入了解成熟醫療機構、專業創新者和合作檢查室夥伴關係如何塑造競爭優勢和診斷服務。

EGFR檢測生態系統內的競爭反映了現有診斷服務提供者、創新定定序專家和服務型參考實驗室之間的平衡。現有服務提供者通常利用其成熟的分銷網路、檢驗的試劑組合以及透過與病理科和腫瘤科長期合作建立的臨床信譽。同時，新參與企業則憑藉技術專長脫穎而出，提供高靈敏度的檢測方法、簡化的工作流程或整合生物資訊學，以加快檢測速度並提高結果解讀的一致性。

經營團隊應採取切實有效、影響深遠的策略行動，以增強 EGFR 診斷領域的臨床應用、供應鏈韌性和協作證據產生。

為了維持EGFR診斷領域的成長動能並抓住策略機遇，產業領導者應優先採取一系列切實可行的措施。首先，應投資於臨床效用證據的收集和驗證，使其符合支付方的要求和臨床醫生的期望，從而縮短從技術推廣到常規應用的過渡期。同時，投資於簡化工作流程、自動化和統一的生物資訊學，將減少操作摩擦，並使此檢測成為高通量檢查室的可行選擇。

對用於綜合臨床、監管和運營方面的見解以進行 EGFR 診斷的定性和定量調查方法進行透明概述

支持這些發現的研究整合了第一手和第二手資料，以建構EGFR診斷領域的全貌。第一手資料包括實驗室主任、分子病理學家、腫瘤學家和診斷採購人員的結構化訪談，以了解實際操作、臨床優先事項和採購促進因素。這些定性觀點與產品資料、監管文件和已發布的臨床指南進行三角驗證，以確保與目前的診療標準保持一致。

概述整合臨床、營運和策略要務以最大限度發揮EGFR診斷臨床價值所需的綜合方法。

EGFR診斷在精準癌症診療系統中佔據關鍵地位，當前的環境既帶來了巨大的機遇，也帶來了營運上的挑戰。定序和微創取樣技術的進步，尤其是其進步，能夠帶來更深入的臨床洞察；而不斷變化的支付方和監管機構的要求，則要求提供相應的證據和嚴謹的營運流程。因此，成功的機構必須將強大的分析能力與切實可行的實施策略相結合，以應對檢查室工作流程、供應鏈風險以及臨床醫生操作的便利性等問題。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按檢測類型分類的EGFR檢測市場

  • 免疫組織化學（IHC）檢測
  • 原位雜合反應（ISH）
  • 次世代定序（NGS）面板
  • 基於PCR的檢測

9. 依檢體類型分類的EGFR檢測市場

  • 液態生物檢體
  • 組織切片檢查

第10章 按應用分類的EGFR檢測市場

  • 乳癌
  • 膠質母細胞瘤
  • 頭頸癌
  • 非小細胞肺癌（NSCLC）

第11章 依最終用戶分類的EGFR檢測市場

  • 學術和研究機構
  • 診斷檢查室
  • 醫院和癌症中心
  • 製藥和生物技術公司

第12章：按地區分類的EGFR檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：按組別分類的EGFR檢測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國EGFR檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國EGFR檢測市場

第16章 中國EGFR檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3B BlackBio Dx Limited
  • Abbexa Ltd.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca plc
  • Beijing ACCB Biotech Ltd.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biomatik Corporation
  • F. Hoffmann-La Roche AG
  • Foundation Medicine, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Luminex Corporation
  • MyBiosource, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN NV
  • RainSure Scientific
  • Shanghai Korain Biotech Co., Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-9A6A6F297449

The EGFR Tests Market was valued at USD 1.70 billion in 2025 and is projected to grow to USD 1.84 billion in 2026, with a CAGR of 8.48%, reaching USD 3.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.70 billion
Estimated Year [2026] USD 1.84 billion
Forecast Year [2032] USD 3.01 billion
CAGR (%) 8.48%

An authoritative orientation to EGFR diagnostics emphasizing clinical impact, laboratory implementation realities, and the convergence of technology and patient care pathways

EGFR (epidermal growth factor receptor) testing has moved from a niche molecular assay to a central pillar of precision oncology, guiding targeted therapies and influencing clinical pathways across multiple tumor types. Recent years have seen diagnostic workflows evolve rapidly as clinicians demand faster, more comprehensive, and less invasive ways to detect actionable EGFR alterations. As a result, laboratory operations, molecular pathology teams, and diagnostic developers are adapting to balance analytical sensitivity with clinical utility, while ensuring results integrate seamlessly into treatment decision-making.

The interplay between technological capability and clinical need shapes the EGFR testing landscape. Advances in sequencing chemistry, improvements in sample preparation, and innovations in bioinformatics have collectively reduced turnaround times and increased confidence in variant detection. At the same time, payer scrutiny and laboratory accreditation frameworks have heightened the importance of validated, reproducible assays. These dynamics create both opportunity and pressure: developers that can demonstrate clinical validity, operational scalability, and cost-effective workflows gain preferential consideration from hospitals, reference labs, and oncology centers.

Looking ahead, the EGFR diagnostic ecosystem will continue to be defined by the need for integrated solutions that connect robust analytical performance with practical laboratory implementation. Decision-makers will prioritize partnerships and platforms that reduce friction across the testing pathway, from specimen collection to actionable reporting. Accordingly, organizations that align technical innovation with clinician-focused reporting and laboratory efficiency are best positioned to influence adoption and patient care.

How technological maturation, evolving clinical guidelines, and changes in payer expectations are jointly redefining EGFR testing practices and care pathways

The EGFR testing landscape is experiencing transformative shifts driven by converging forces: technological maturation, changes in clinical guidelines, and evolving value-based care models. Next-generation sequencing and highly sensitive PCR-based assays are moving beyond single-analyte testing to enable multiplexed, hypothesis-free approaches that capture a broader spectrum of actionable alterations. This transition amplifies the clinical relevance of EGFR testing in both initial diagnosis and resistance monitoring, thereby reshaping testing algorithms across oncology practices.

Simultaneously, minimally invasive sampling approaches and liquid biopsy innovations are lowering barriers to serial monitoring, making it feasible to track clonal evolution and emergent resistance in real time. As a result, clinical workflows are beginning to incorporate dynamic testing strategies that inform adaptive therapy decisions. Payer policies and evidence generation efforts are also responding, with reimbursement increasingly tied to demonstrated clinical utility and clear pathways for integration into care protocols.

Operationally, laboratories are reconfiguring to handle greater throughput and more complex data streams, investing in automation, standardized bioinformatics pipelines, and robust quality management systems. These shifts create new collaboration models between diagnostic developers, reference labs, and healthcare providers. Strategic entrants that can combine validated assays with seamless informatics and reporting frameworks will influence the standard of care and capture meaningful clinical and commercial traction.

Analyzing the downstream operational and strategic consequences of tariff changes on diagnostic supply chains, procurement decisions, and continuity of EGFR testing services

The introduction of new tariff regimes and trade policy adjustments can materially affect the operational and cost structure of diagnostic supply chains, with particular implications for reagent access, instrument procurement, and cross-border service models. Tariffs that increase the landed cost of imported reagents and instruments create pressure on laboratories to rationalize supplier portfolios, renegotiate procurement terms, and consider regional sourcing alternatives. This in turn influences test selection and the pace at which new technologies are adopted across diverse institutional settings.

Moreover, tariffs can drive a re-evaluation of localized manufacturing and distribution partnerships. Diagnostic companies and labs may pursue nearshoring strategies or strategic inventory management to mitigate supply risk and maintain continuity of patient testing services. These adaptations often require upfront investment in supply chain redesign, regulatory revalidation for alternative product sources, and operational changes to manage inventory and expiration risks. Consequently, organizations that anticipate tariff impacts and proactively diversify procurement channels will preserve service levels and reduce the likelihood of disruptive price pass-through to end-users.

In parallel, tariffs can reshape collaboration patterns, prompting increased reliance on regional service providers and collaborative networks that reduce dependence on long-haul shipments. For clinical programs that rely on timely EGFR results for therapy selection, preserving turnaround time becomes a central operational metric. Therefore, leaders should evaluate not only direct cost implications but also downstream effects on access, clinical scheduling, and patient outcomes when assessing tariff-related strategy adjustments.

Nuanced segmentation intelligence that dissects assay modalities, specimen strategies, clinical applications, and end-user requirements to inform targeted diagnostic strategies

A clear understanding of segmentation dynamics is essential to align product development and commercial strategies with clinical and laboratory needs. When viewed through the lens of test type, Immunohistochemistry tests, In Situ Hybridization assays, Next-Generation Sequencing panels, and PCR-based assays each occupy distinct positions in diagnostic workflows, reflecting trade-offs between analytic resolution, turnaround time, and cost. Immunohistochemistry and ISH often serve as initial, pathology-driven triage tools, while PCR-based assays and NGS panels provide higher-resolution molecular characterization that supports targeted therapy selection.

Sample type further influences operational design and clinical value propositions. Liquid biopsy offers minimally invasive access to circulating tumor DNA and supports longitudinal monitoring, enabling detection of resistance mutations without repeat tissue procedures. Tissue biopsy remains indispensable for comprehensive histopathologic assessment and for scenarios where tumor content or variant allele frequency requires direct tumor sampling. Integrating both sample approaches into testing algorithms enhances clinical flexibility and can improve the capture of actionable alterations across treatment timelines.

Application-specific considerations also shape demand and evidence generation priorities. EGFR testing for Non-Small Cell Lung Cancer represents an established clinical imperative, while applications in breast cancer, glioblastoma, and head and neck cancers are driving exploratory and translational research that may expand testing indications. Finally, end-user segmentation highlights varied purchasing and operational drivers: academic and research institutions prioritize innovation and comprehensive panels, diagnostic laboratories emphasize throughput and reproducibility, hospitals and cancer centers require integrated reporting and clinical decision support, and pharmaceutical and biotechnology companies focus on companion diagnostics and trial-ready assay platforms. Strategic initiatives that recognize these differentiated needs can more effectively target product features, evidence packages, and commercialization approaches.

How divergent regulatory landscapes, reimbursement models, and infrastructure maturity across major global regions influence EGFR diagnostic adoption and strategic planning

Regional dynamics exert a significant influence on regulatory pathways, reimbursement frameworks, and adoption timelines for EGFR diagnostics. In the Americas, established clinical guidelines and extensive oncology networks often drive early clinical uptake of advanced molecular testing, while accredited reference laboratories and integrated health systems set high expectations for analytical performance and reporting. These conditions encourage the adoption of multiplexed assays and structured result interpretation that support precision treatment decisions.

In Europe, the Middle East & Africa region, heterogeneity in regulatory approaches and healthcare funding models creates varied adoption patterns. Some jurisdictions emphasize centralized testing and national reference laboratories, while others rely on private laboratory networks. By contrast, regulatory harmonization initiatives and regional clinical collaboratives can accelerate adoption in markets that align reimbursement and clinical pathways with diagnostic evidence.

The Asia-Pacific region demonstrates rapid expansion of molecular testing capacity alongside strong investments in diagnostic infrastructure. Innovative models that combine high-volume reference testing with increasingly capable local manufacturers are reshaping access to advanced assays. Across all regions, local regulatory clarity, reagent supply stability, and clinician education are pivotal to sustained adoption. Organizations prepared to navigate these regional nuances and to invest in targeted evidence generation and local partnerships will achieve more predictable diagnostic integration and broader clinical impact.

Insights into how established providers, specialized innovators, and collaborative laboratory partnerships are shaping competitive advantages and diagnostic offerings

Competitive dynamics within the EGFR testing ecosystem reflect a balance between incumbent diagnostic providers, innovative sequencing specialists, and service-oriented reference laboratories. Incumbents often leverage established distribution networks, validated reagent portfolios, and clinical trust built through long-standing relationships with pathology and oncology departments. In contrast, newer entrants differentiate through technological specialization-offering higher sensitivity assays, streamlined workflows, or integrated bioinformatics that reduce time-to-answer and improve interpretive consistency.

Partnerships between diagnostic developers and clinical laboratories are increasingly common as they accelerate clinical validation and facilitate market access. Reference labs play a critical role in bridging early clinical demand with scalable service delivery, while collaborations with pharmaceutical and biotech companies ensure diagnostics align with therapeutic pipelines and trial needs. Additionally, investment in regulatory strategy and evidence generation enables companies to demonstrate clinical utility and support reimbursement discussions, strengthening commercial positioning.

Mergers, strategic alliances, and co-development agreements are reshaping capability stacks, enabling integrated offerings that combine sample-to-result workflows with clinical reporting and decision support. Companies that prioritize interoperability, robust quality systems, and clinician-facing reporting formats will secure long-term adoption. Ultimately, success depends on demonstrating that diagnostic solutions not only meet analytical expectations but also integrate seamlessly into care pathways and support measurable improvements in clinical decision-making.

Practical, high-impact strategic moves executives should implement to strengthen clinical adoption, supply resilience, and collaborative evidence generation for EGFR diagnostics

Industry leaders should prioritize a set of pragmatic actions to sustain momentum and capture strategic opportunities in EGFR diagnostics. First, invest in demonstrating clinical utility through focused evidence generation that aligns with payer requirements and clinician expectations, thereby shortening the path from adoption to routine use. Parallel investments in streamlined workflows, automation, and harmonized bioinformatics will reduce operational friction and position assays as practical choices for high-volume laboratories.

Second, pursue strategic supply chain resilience by diversifying manufacturing and distribution partners, optimizing inventory strategies, and evaluating regional sourcing to mitigate tariff and logistics risk. These measures preserve uninterrupted service delivery and protect pricing stability. Third, cultivate partnerships across the clinical ecosystem-including oncology centers, pathology networks, and pharmaceutical developers-to coordinate evidence generation, co-develop companion diagnostic frameworks, and ensure assays are trial-ready when therapeutic opportunities arise.

Finally, prioritize clinician-centric reporting and decision support that translate complex molecular findings into clear, actionable recommendations. Investing in user experience for both laboratory personnel and treating physicians enhances confidence in results and accelerates clinical integration. By combining robust evidence, operational excellence, supply chain foresight, and clinician-focused tools, leaders can sustainably expand the clinical impact of EGFR diagnostics.

A transparent overview of qualitative and quantitative research techniques used to synthesize clinical, regulatory, and operational insights for EGFR diagnostics

The research underpinning these insights integrates primary and secondary data sources to construct a holistic view of the EGFR diagnostic environment. Primary inputs included structured interviews with laboratory directors, molecular pathologists, oncology specialists, and diagnostic procurement leads to capture operational realities, clinical priorities, and procurement drivers. These qualitative perspectives were triangulated with product literature, regulatory documents, and published clinical guidance to ensure alignment with current standards of care.

Analytical methods combined comparative technology assessments with workflow mapping to evaluate assay fit across clinical scenarios and laboratory infrastructures. Supply chain and procurement analyses focused on supplier concentration, import dependencies, and logistical considerations that affect reagent and instrument availability. Additionally, scenario analysis was used to consider the operational impacts of policy shifts, such as changes in trade tariffs and regional regulatory updates, on testing access and continuity.

Throughout the research, emphasis was placed on reproducibility and transparency. Findings were validated through iterative stakeholder consultations and cross-checked against publicly available clinical guidance and regulatory notices. This approach ensures that recommendations are grounded in real-world practice, reflect contemporary regulatory considerations, and remain relevant to decision-makers responsible for diagnostic strategy and implementation.

A synthesis of clinical, operational, and strategic imperatives that outlines the integrated approach required to maximize the clinical value of EGFR diagnostics

EGFR diagnostics occupy a pivotal position in the precision oncology continuum, and the current environment presents both substantive opportunities and operational challenges. Technological advancements-particularly in sequencing and minimally invasive sampling-enable richer clinical insights, while evolving payer and regulatory expectations require commensurate evidence and operational rigor. Successful organizations will therefore integrate robust analytical performance with pragmatic implementation strategies that address laboratory workflows, supply chain risk, and clinician usability.

Sustained progress will depend on collaborative evidence generation that links diagnostic findings to meaningful clinical outcomes, as well as on strategic partnerships that align diagnostic capabilities with therapeutic development and patient care pathways. Organizations that invest in resilient procurement models, localized partnerships, and clinician-focused reporting will preserve access and influence adoption patterns across diverse healthcare settings. In this way, EGFR diagnostics can continue to expand their clinical utility and support more precise, adaptive oncology care.

Ultimately, the path forward is one of integration-melding scientific rigor with operational excellence and stakeholder alignment to ensure that diagnostic innovation translates into improved treatment decisions and better patient outcomes. Decision-makers who act with strategic clarity and execute on these priorities will capture the greatest clinical and commercial benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. EGFR Tests Market, by Test Type

  • 8.1. Immunohistochemistry (IHC) Tests
  • 8.2. In Situ Hybridization (ISH)
  • 8.3. Next-Generation Sequencing (NGS) Panels
  • 8.4. PCR-based Assays

9. EGFR Tests Market, by Sample Type

  • 9.1. Liquid Biopsy
  • 9.2. Tissue Biopsy

10. EGFR Tests Market, by Application

  • 10.1. Breast Cancer
  • 10.2. Glioblastomas
  • 10.3. Head and Neck Cancers
  • 10.4. Non-Small Cell Lung Cancer (NSCLC)

11. EGFR Tests Market, by End-Users

  • 11.1. Academic & Research Institutions
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Cancer Centers
  • 11.4. Pharmaceutical & Biotechnology Companies

12. EGFR Tests Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. EGFR Tests Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. EGFR Tests Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States EGFR Tests Market

16. China EGFR Tests Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3B BlackBio Dx Limited
  • 17.6. Abbexa Ltd.
  • 17.7. Abbott Laboratories
  • 17.8. Agilent Technologies, Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Beijing ACCB Biotech Ltd.
  • 17.11. Bio-Rad Laboratories, Inc.
  • 17.12. Bio-Techne Corporation
  • 17.13. Biomatik Corporation
  • 17.14. F. Hoffmann-La Roche AG
  • 17.15. Foundation Medicine, Inc.
  • 17.16. Guardant Health, Inc.
  • 17.17. Illumina, Inc.
  • 17.18. Luminex Corporation
  • 17.19. MyBiosource, Inc.
  • 17.20. Myriad Genetics, Inc.
  • 17.21. QIAGEN N.V.
  • 17.22. RainSure Scientific
  • 17.23. Shanghai Korain Biotech Co., Ltd.
  • 17.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EGFR TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EGFR TESTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EGFR TESTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EGFR TESTS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EGFR TESTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EGFR TESTS MARKET SIZE, BY END-USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EGFR TESTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EGFR TESTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EGFR TESTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EGFR TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EGFR TESTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EGFR TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EGFR TESTS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY (IHC) TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EGFR TESTS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY (IHC) TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EGFR TESTS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY (IHC) TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EGFR TESTS MARKET SIZE, BY IN SITU HYBRIDIZATION (ISH), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EGFR TESTS MARKET SIZE, BY IN SITU HYBRIDIZATION (ISH), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EGFR TESTS MARKET SIZE, BY IN SITU HYBRIDIZATION (ISH), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EGFR TESTS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS) PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EGFR TESTS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS) PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EGFR TESTS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS) PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EGFR TESTS MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EGFR TESTS MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EGFR TESTS MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EGFR TESTS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EGFR TESTS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EGFR TESTS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EGFR TESTS MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EGFR TESTS MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EGFR TESTS MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EGFR TESTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EGFR TESTS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EGFR TESTS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EGFR TESTS MARKET SIZE, BY GLIOBLASTOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EGFR TESTS MARKET SIZE, BY GLIOBLASTOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EGFR TESTS MARKET SIZE, BY GLIOBLASTOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EGFR TESTS MARKET SIZE, BY HEAD AND NECK CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EGFR TESTS MARKET SIZE, BY HEAD AND NECK CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EGFR TESTS MARKET SIZE, BY HEAD AND NECK CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EGFR TESTS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EGFR TESTS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EGFR TESTS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EGFR TESTS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EGFR TESTS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EGFR TESTS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EGFR TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EGFR TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EGFR TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EGFR TESTS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EGFR TESTS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EGFR TESTS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EGFR TESTS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EGFR TESTS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EGFR TESTS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EGFR TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS EGFR TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA EGFR TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EGFR TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 95. GCC EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. GCC EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 110. G7 EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. G7 EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. G7 EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. G7 EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. G7 EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 115. NATO EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NATO EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NATO EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NATO EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NATO EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EGFR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES EGFR TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED STATES EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA EGFR TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA EGFR TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. CHINA EGFR TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA EGFR TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA EGFR TESTS MARKET SIZE, BY END-USERS, 2018-2032 (USD MILLION)